View Older Stories View More Recent Stories
-
Merck (MRK) Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab
-
Merck's (MRK) KEYTRUDA Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment
-
Merck (MRK) Receives Positive EU CHMP Opinion for WELIREG
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Could Moderna stock be due for rally in 2025? Jefferies weighs in
-
Merck (MRK) Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
-
Merck Earns Top Spot on Newsweek’s List of America’s Most Responsible Companies 2025
-
Merck (MRK) and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study Evaluating LAGEVRIO for the Treatment of COVID-19 in High-Risk Adults
-
HSBC Upgrades Merck (MRK) to Buy
-
Merck (MRK) Granted FDA Breakthrough Therapy Designation to Sacituzumab Tirumotecan
-
Merck (MRK) PT Lowered to $110 at Bernstein SocGen Group as 'Gardasil overhang continues'
-
BMO Capital Reiterates Outperform Rating on Merck (MRK)
-
Merck (MRK) Announces Phase 3 ZENITH Trial Evaluating WINREVAIR Met Primary Endpoint at Interim Analysis
-
Merck's (MRK) WELIREG Approved in China for Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
-
Merck (MRK) Announces Surendralal Karsanbhai Elected to Board of Directors
-
CFRA Upgrades Merck (MRK) to Buy (midday)
-
Merck (MRK) Declares $0.81 Quarterly Dividend; 3.4% Yield
-
JPMorgan Reiterates Overweight Rating on Merck (MRK)
-
Merck (MRK) Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
-
Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemo as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid MPM
-
Merck (MRK) PT Raised to $148 at Jefferies
-
Merck (MRK) call put ratio 1 call to 5.9 puts
-
Merck (MRK) Enters into Exclusive Global License for LM-299
-
Merck (MRK) reports KOSELUGO Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo
-
Merck (MRK) PT Lowered to $136 at BMO Capital
-
Leerink Partners Reiterates Outperform Rating on Merck (MRK)
-
Merck (MRK) Tops Q3 EPS by 7c; narrows guidance range
-
Merck (MRK) call put ratio 2.6 calls to 1 put into quarter results
-
Merck (MRK) call put ratio 2.2 calls to 1 put into quarter results
-
Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA
-
Barclays Reiterates Overweight Rating on Merck (MRK)
-
Merck's (MRK) KEYTRUDA Receives 30th Approval From EU Commission With Two New Indications in Gynecologic Cancers
-
Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
-
Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
-
Merck's (MRK) MK-1654 Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
-
Merck's (MRK) CAPVAXIVE Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
-
Truist Securities Reiterates Buy Rating on Exelixis (EXEL)
-
Citi Reiterates Buy Rating on Exelixis (EXEL)
-
Stephens Reiterates Equal Weight Rating on Exelixis (EXEL)
-
Exelixis (EXEL) and Merck (MRK) Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA
-
Merck (MRK) PT Lowered to $132 at Truist Securities
-
Merck's (MRK) KEYTRUDA Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
-
TD Cowen Reiterates Buy Rating on Merck (MRK)
-
Merck (MRK) Completes Acquisition of CN201 from Curon Biopharmaceutical
-
Evaxion Biotech (EVAX) expands vaccine development collaboration with MSD
-
Merck (MRK) to Present New Long-Term Data for Tulisokibart
-
Merck (MRK) Provides Update on Phase 3 KEYFORM-007 Trial of Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab
-
Merck's (MRK) KEYTRUDA Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma
-
Merck Animal Health (MRK) Announces Expansion of NOBIVAC NXT Platform
-
Merck (MRK) Receives Positive EU CHMP Opinions for KEYTRUDA Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
